Pulmonary hypertension is a substantial global health issue. All age groups are affected, with growing importance in its effect on the elderly. Present estimates suggest a prevalence of ~1% of the global population, which increases up to 10% in individuals 65 years or older. Delayed, incomplete, and inappropriate diagnoses of pulmonary hypertension are common and reported in as many as 85% of at-risk patients. Sadly, development of pulmonary hypertension is associated with worsening health and increased risk of death.
How do you define and diagnose pulmonary hypertension?
Pulmonary hypertension is defined by either a mean pulmonary artery pressure at rest of 20 mm Hg or more as measured by a right heart catheterization (RHC) or a right ventricular systolic pressure (RVSP) of 30 mm Hg or more as measured by an echocardiogram. An RHC is the diagnostic gold standard and an essential component in the evaluation of pulmonary hypertension. While an echocardiogram can be a useful screening tool for the presence of pulmonary hypertension, it only provides an estimate of RVSP. An RHC is absolutely required to confirm the diagnosis, assess the severity of hemodynamic impairment, provide risk assessment, and guide pulmonary hypertension-specific therapy.
The threshold to perform a left heart catheterization (LHC) in addition to an RHC should be low in patients with risk factors for heart disease and when the measurement of left ventricular end-diastolic pressure (LVEDP) is important to avoid potential misclassification of pulmonary hypertension.
What are the hemodynamic definitions?
There are three major hemodynamic definitions of pulmonary hypertension: 1) pre-capillary, 2) isolated post-capillary, and 3) combined pre- and post-capillary. These hemodynamic definitions are determined according to various combinations of pulmonary artery pressure (PAP), pulmonary capillary wedge pressure (PCWP), diastolic pressure gradient (DPG), transpulmonary pressure gradient (TPG), cardiac output (CO), and pulmonary vascular resistance (PVR). These hemodynamic definitions can be determined at the time of an RHC, again underscoring the importance of an RHC in the diagnosis and management of pulmonary hypertension, to allow for categorizing into a specific World Health Organization (WHO) group.
What are the clinical classifications or groups (i.e. WHO groups)?
Additional laboratory, diagnostic, and imaging tests are completed to further characterize the possible etiology of pulmonary hypertension. The additional tests include, but are not limited to:
- Blood tests and immunology
- Electrocardiogram
- Chest X-ray
- 6-minute walk test
- Echocardiogram with bubble study
- Abdominal ultrasound
- Pulmonary ventilation/perfusion (V/Q) scan
- High-resolution CT scan without contrast
- Pulmonary function test with arterial blood gases
- Sleep study
- Genetic testing, in select patients
At this point, all the information obtained from the RHC and additional testing listed above allows for categorizing into a specific WHO group. The clinical classification of pulmonary hypertension is intended to categorize multiple clinical conditions into five groups according to their similar clinical presentation, pathological findings, hemodynamic characteristics, and treatment strategy. The classifications or groups are defined by the World Health Organization (WHO) and are referred to as WHO group 1-5:
WHO Group 1 (due to pulmonary arterial hypertension [PAH])
- idiopathic, heritable, drug- or toxin-induced, and associated with connective tissue disease, HIV infection, portal hypertension, congenital heart disease, or schistosomiasis
- pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis (PVOD/PCH)
- diagnosing PAH requires exclusion of comorbid cardiac, lung, thromboembolic, and other diseases that predispose to increasing pulmonary artery pressures
WHO Group 2 (due to left-sided heart disease)
- left ventricular systolic dysfunction, left ventricular diastolic dysfunction, valvular heart disease, or specific congenital abnormalities
WHO Group 3 (due to lung disease and/or hypoxia)
- chronic obstructive pulmonary disease, interstitial lung disease, other mixed restrictive or obstructive lung disease, sleep-disordered breathing, or chronic exposure to high altitude
WHO Group 4 (due to chronic thromboembolic pulmonary hypertension [CTEPH] and other pulmonary artery obstructions)
- chronic thromboembolic pulmonary hypertension or other pulmonary artery obstructions (e.g., angiosarcoma, other intravascular tumors, arteritis, congenital stenoses, and parasites)
WHO Group 5 (due to unclear and/or multifactorial mechanisms)
- renal disease and various hematological, systemic, or metabolic disorders
Certain WHO groups are more common than others. For example, left-sided heart disease (i.e. WHO group 2), particularly heart failure with preserved ejection fraction (HFpEF), is becoming a leading cause of pulmonary hypertension, probably affecting 5-10% of individuals aged 65 years or older. The bottom line is that determining your WHO group classification is critically important to guide subsequent treatment strategies.
What is exercise-induced pulmonary hypertension?
As stated above, the current definition of pulmonary hypertension is a mean pulmonary artery pressure at rest of 20 mm Hg or more. However, patients with occult or milder forms of pulmonary vascular disease or left-sided heart disease might fail to meet this resting threshold but still develop shortness of breath or dyspnea with exertion and exercise. Exercise-induced changes in mean pulmonary artery pressure and pulmonary capillary wedge pressure may be helpful in certain clinical situations, 1) differentiating WHO group 1 versus WHO group 2, 2) identifying symptomatic left-sided heart disease, and 3) identifying symptomatic exercise-induced WHO group 1. In these situations, an exercise RHC (i.e. a symptom-limited supine or upright bicycle with invasive hemodynamic monitoring) may be required for further evaluation. Here is an example of a typical set-up for a supine bicycle in a heart catheterization laboratory:

How do you risk stratify and provide a risk assessment?
Regular risk assessment of patients with pulmonary hypertension is strongly recommended. A comprehensive risk assessment is required since there is no single determinant that provides enough prognostic information. The most important question to be addressed at every clinic visit, is the patient compatible with a good long-term prognosis (i.e. meet low-risk criteria)? To answer this question, a structured approach is needed, and all pulmonary hypertension specialists should have a checklist (see below) to help provide a comprehensive risk assessment:

Achieving low clinical risk also functions as the primary treatment goal, thus treatment should be tailored to achieve and maintain a low-risk status.
What is the treatment?
There is supportive therapy and specific drug therapy (i.e. pulmonary hypertension-specific therapy) for pulmonary hypertension.
Supportive therapy includes:
- Oral anticoagulants, in select patients
- Diuretics, in patients with fluid overload
- Oxygen, in patients with correctable oxygen desaturation
- Digoxin, in patients with atrial tachyarrhythmias
- Iron substitution, in patients with iron deficiency
Pulmonary hypertension-specific therapy includes:
- Calcium channel blockers (CCBs), only in select patients: nifedipine and amlodipine
- Phosphodiesterase type 5 (PDE-5) inhibitors and soluble guanylate cyclase (sGC) stimulators: sildenafil, tadalafil, and riociguat
- Endothelin receptor antagonists (ERAs): bosentan, ambrisentan, and macitentan
- Prostacyclin analogues and prostacyclin receptor agonists (i.e. prostanoids): epoprostenol, iloprost, treprostinil, and selexipag
Over the past several years, some important trends have appeared in the management of pulmonary hypertension. The phosphodiesterase type 5 (PDE-5) inhibitors or soluble guanylate cyclase (sGC) stimulators, endothelin receptor antagonists (ERAs), and prostaglandin replacement therapies (i.e. prostanoids), administered as monotherapy or in sequential combination, now have proven effectiveness in the treatment of pulmonary hypertension. Also, findings from the AMBITION trial mark an exciting shift in pulmonary hypertension-specific therapy by providing evidence in favor of initial combination therapy over monotherapy for newly diagnosed pulmonary hypertension patients.
What is the prognosis?
Pulmonary hypertension has evolved into a treatable disease with decreased morbidity and improved survival. The REVEAL registry, which tracks patients with PAH in the United States, reported that the 1- and 5-year survival rates of patients were 90% and 65%, respectively. Similar findings were observed in Spain, the United Kingdom, and China that the 1- and 3-year survival rates of patients receiving combination therapy for PAH were 96% and 84%, respectively. The course of pulmonary hypertension is one of gradual decline with sporadic episodes of acute worsening. It is difficult to predict when pulmonary hypertension patients will die, as death may come either suddenly or slowly because of progressive right heart failure.
Pulmonary hypertension has evolved into a modern disease with a high standard for defining the diagnosis and treatment goals. However, unfortunately, there is a lack of awareness among non-pulmonary hypertension specialists regarding the importance of early and accurate diagnosis and treatment.
It is important to know your specific WHO group, as well as the treatment strategy for your pulmonary hypertension, so that you can be a better participant in your health care. Current evidence indicates that pulmonary hypertension management at a specialty care center is associated with improvements in survival and hospitalizations. Thus, finding a pulmonary hypertension specialist in your area is critically important. Take control of your health!
Very well explained, thank you for sharing this article.
Thank you for your feedback.
Thank you for this great article. I recently had an Echocardiogram which said my estimated right ventricular systolic pressure is moderately elevated at 41.4 mmHg. However, unfortunately the doctor was very vague about what this means at all and I am completely in the dark. Does this mean I have PAH? If so, does this number naturally fluctuate or once it is a high number it stays a high number? If that is the case, I suppose that is what makes it a progressive disease. I am a male, 62 years old and 2.5 years ago I had an MCI which required stenting of the RCA. I am generally in good shape and active, I belive the MCI was due to mostly genetic high blood lipids. I also had a CTO of the LAD and that was successfully stented 2 months after the RCA. I just had the Echo last week. My O2 saturation seems to average about 95, my pulse is usually 60 and I do know that my breaths per minute is less than 10. I go up and down stairs with no problem and have no shortness of breath. Any input you have would be greatly appreciated. I am very much in the dark. Thank you so much!
The only way to know for sure if you have pulmonary hypertension is to have a right heart catheterization (RHC). However, given your heart disease and stents, this is most likely WHO Group 2 pulmonary hypertension due to left-sided heart disease. Thus, the treatment for your pulmonary hypertension is actually the treatment of your heart disease with medications (for your blood cholesterol and blood pressure), diet (low salt), and exercise (mild-to-moderate exercise with resistance training). If your estimated right ventricular systolic pressure does not improve to <40 mm Hg after 6-12 months with those above changes, then proceeding with a RHC for further evaluation of your pulmonary hypertension would be reasonable.
I have recently been told that I have Pulmonary Hypertension. I am still reading up and learning more about it. I have noticed an increase in my shortness of breath and in the last week I have developed a horrible dry “barking sound” cough that I can’t explain. I am scheduled for a sleep study and echocardiogram this coming week and then the doctor will decide what the next best step is from there. I am however very concerned because apparently, they diagnosed the PH in 2021 but no one told me about it and now it has progressed. Is there anything you can suggest I do to try and ease the cough. My chest hurts and it is painful to keep coughing like this. Thanks
I would be better to sort out the reason for your cough and then be able to treat it from there. An echocardiogram to estimate your pulmonary pressures, and then a right heart catheterization to confirm the pulmonary pressures may be needed.
My echocardiogram results say that I have pulmonary hypertension. My stress test says that my heart is in great shape. I have an appointment with a pulmonologist coming up, but is my prognosis better than five years due to my healthy heart?
A stress test evaluates the left side (i.e. left ventricle) of your heart, not the right side (i.e. right ventricle). It is the right side of the heart that is most important to evaluate and monitor in pulmonary hypertension. Your pulmonologist may suggest a right heart catheterization to further evaluate the pulmonary hypertension based on the findings on your echocardiogram and symptoms.
Hi, I am a 71 y/o female. I had an echo done, which came back normal (with mild asymmetric LVH being the only abnormality, but my RVSP was 53. I have mild-moderate COPD, but not many symptoms other than general, relatively mild SOB. The echo report doesn’t say anything about PAH, just that my RVSP was 53. Should I get a RHC? Thank you!
That is a good question. It depends on your symptoms as well as the size/function of the right ventricle, there are some nuances in deciding who needs a RHC and who can just be closely monitored.
Sorry for the late reply. My right ventricle size/function is normal. Right Ventricular End Diastole is 2.9cm.
That is reassuring regarding your RSVP, however the decision about a RHC will be between you and your physician.
Overall though, would you say that it’s common for someone to have such a high RVSP and not show an elevated pressure via RHC? Thank you for responding.
Yes, it is somewhat common to have an elevated RSVP by echocardiogram but normal pulmonary artery pressures by RHC (as well as vice versa). Thus, the RHC is the gold standard for diagnosing pulmonary hypertension and echocardiogram is a great screening tool.
My recent echo report states that pulmonary pressure was unable to be obtained due to low triscupid jet velocity. Would this rule out pulmonary hypertension? I have a yearly echo due to having mitral valve prolapse, but I’m also monitored for the development of Pulmonary Hypertension due to having Lupus.
No, having pulmonary pressure unable to be assessed due to low triscupid jet velocity would not rule out pulmonary hypertension. Yearly echocardiograms for surveillance of your mitral valve prolapse and pulmonary hypertension would be recommended in your case.
Hi I have recently had ecg ctca vq scan (2020 multiple small pul emboli mostly resolved no longer on anticoags. Told ecg essentially normal 30% lad prox lesion cholesterol 9 on treatment.
Presented to Ed recently with systolic bp up to 220 pulsatile tinnitus tachycardia. Echo 3 weeks ago showed mild plus tricuspid regurgitation plus mod to severe pulmonary pressure, 57. in Ed another echo tech said it wasn’t that high 43 but my bp had dropped significantly when I had echo done.Was put on tadalifil 2.5 daily with no info. Does this mean I have pulmonary hypertension have been housebound 80% over past 4 years. Now 95% dysfunctional. Just need info re why I was given this drug. I don’t have a penis or a prostate! Dr doesn’t respond says come back in 6 weeks. Have been home 4 days like an invalid. I know you will say contact dr but he’s obviously not worried, I am done have no life.
It is hard to say. Based on what you are describing 1) there was no confirmation of pulmonary hypertension (PH) or even evidence to start PH-specific therapy (i.e. you need a right heart catheterization) and 2) Adcirca (tadalafil) is usually started at 20mg daily for pulmonary hypertension (so, not sure about the tadalafil 2.5mg daily dose). Unfortunately, it appears you will need to wait for your doctor’s appointment to get any further answers.
Hi dr, my Lung Rx showed flattening diaphragm domes, slimming, strengthening Lung trama with suspected COPD. My hart ECG showed slightly mitralvalve insufficiency, thickened anterior mitral valve leaflet and slightly tricuspid insufficiency. RA And RV not dilated but RV is slightly hypocontractile. PAP = 22 mmHg.
These tests were in march after 6 months with extreme fatigue, dyspnea after little exertion and chest pressure, Lowering bp and tachycardia +120 after standing 10min. Resting hart rate 65.
In september last year i had covid infection with a week of lung hypoxia Sp02 between 85-92%. I have visible small blood vessels inflammation on my feet and toes so i worry my ongoing long covid inflammation and COPD inflammation are slowly inducing Pulmonary hypertension.. My GP says i don’t need to worry but i feel she doesnt take me serious..
You think its worth for a CT scan, heart catheter and lung function test to rule out pulmonary hypertension or does my ECG rules it out already even with PAP above 20mghh? I suspected first autonomic dysfunction bcz of orthostatic tachycardia and blood pooling but my dyspnea keeps gettin worse after a year so is it possible it could be POTS COPD and PH at the same time? thank you in advance
It is difficult to say, your symptoms are very general. I would say that the PASP = 22 mm Hg, is reassuring. Given your symptoms, obtaining PFTs +/- a chest CT scan would be reasonable, but would defer to the Pulmonologist taking care of your case. From what you have described, pursing a RHC at this time may be a little premature.